Aspirin added significantly to the benefits of a low-cost ‘polypill’ approach for primary prevention of cardiovascular disease in an intermediate-risk population, the TIPS-3 study has found, according to research published in The New England Journal of Medicine. Aspirin has thus proved its mettle in primary prevention, the lead author told the American Heart Association meeting.

People who got the polypill in the trial had a borderline lower incidence of composite CVD events (cardiovascular death, MI, stroke, heart failure, resuscitated cardiac arrest, or arterial revascularisation with evidence of ischaemia) over six years compared with the placebo group (4.4% vs 5.5%, HR 0.79, 95% CI 0.63-1.00), writes Nicole Lou in a MedPage article on 13 November 2020…..more